We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Guangzhou Pluslife Biotech Co., Ltd.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Bone Turnover Markers Associated With Mortality Risk in Older Men

By LabMedica International staff writers
Posted on 19 Jul 2022
Print article
Image: Bone Turnover Markers Including Undercarboxylated Osteocalcin Are Associated With Mortality Risk in Older Men (Photo courtesy of Blood Tests in London)
Image: Bone Turnover Markers Including Undercarboxylated Osteocalcin Are Associated With Mortality Risk in Older Men (Photo courtesy of Blood Tests in London)

Osteocalcin in its undercarboxylated form (ucOC) may influence diabetes risk; however, its relationship with all-cause and cause-specific mortality is unclear. Whether other bone turnover markers (BTMs) are associated with mortality risk differently from ucOC also remains uncertain.

There are inconsistent findings regarding the association between ucOC concentrations and cardiovascular disease (CVD) risk. An increase in bone turnover with age may predispose to reduced bone mineral density and increased risk of fractures, also associated with incident CVD events.

Medical Scientist at University of Western Australia (Perth, Australia) conducted a prospective cohort study of 3,871 community-dwelling men, aged 77.0 ± 3.6 years at baseline, followed for a median of 12.3 years. Approximately 95% of participants were of White ethnic origin. Prevalent diabetes, cardiovascular disease, cancer, Paget’s disease of the bone, osteoporosis, bone fractures within the past 12 months, and current bisphosphonate or glucocorticoid use were collected using questionnaires.

Serum undercarboxylated osteocalcin, serum total osteocalcin (TOC), procollagen type I N-propeptide (PINP), and collagen type 1 C-terminal cross-linked telopeptide (CTX) were measured from blood samples. Serum TOC, PINP, and CTX were measured by electrochemiluminescence immunoassay using a Modular E170 analyzer (Roche Diagnostics, North Ryde, Australia). The concentration of ucOC in the supernatant was measured using the same method as for TOC.

The investigators reported that during a median follow-up time of 12.3 years, 61% of the study cohort died. The primary cause of death was 27% each for both CVD and cancer. In fully adjusted analyses, each standard deviation increase was statistically significant in concentrations of undercarboxylated osteocalcin (hazard ratio [HR] = 1.12), procollagen type 1 N-propeptide (HR = 1.06) and collagen type 1 C-terminal cross-linked telopeptide (HR = 1.13) was associated with an increased risk for all-cause mortality. The associations were similar after 436 men with an incident fracture at follow-up were excluded.

The risk for CVD mortality was increased with each standard deviation increase in undercarboxylated osteocalcin (HR = 1.13) and collagen type 1 C-terminal cross-linked telopeptide (HR = 1.12). No associations were observed between CVD mortality and total osteocalcin or procollagen type 1 N-propeptide. A higher risk for cancer mortality was observed with each standard deviation increase in collagen type 1 C-terminal cross-linked telopeptide (HR = 1.12). No other bone turnover markers were associated with cancer mortality risk.

Bu Yeap, MBBS, PhD, a Professor of Endocrinology and senior author of the study, said, “Higher mortality was seen in men who had higher concentrations of undercarboxylated osteocalcin, and also those with higher concentrations of two other bone turnover markers, procollagen type 1 N-propeptide and collagen type 1 C-terminal cross-linked telopeptide. Therefore, the underlying pathway appears to involve bone turnover, in general, and not specifically undercarboxylated osteocalcin. The results were similar even after excluding men who experienced bone fractures during follow-up, so there may be a broader effect of higher bone turnover to increase susceptibility to a range of conditions contributing to death.”

The authors concluded that higher bone turnover, assessed by different BTMs including ucOC, PINP, and CTX, is a biomarker for all-cause mortality in older men. Higher concentrations of CTX were also associated with cancer deaths. The study was published on June 11, 2022 in the Journal of Bone and Mineral Research.

Related Links:
University of Western Australia 
Roche Diagnostics 

Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
Automatic IFA Processor
M. Tuberculosis Indirect Test
Hemolysing Reagent
Dialyse-BA 5D

Print article



view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more


view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more


view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.